PTGS2 and colorectal carcinoma: A study by Burns et al. [68] shows that orally taking 600 mg/day of cyclooxygenase-2 inhibitors (in this case aspirin) for over 2 years reduces incidence rates of CRC associated with LS, but additional studies are needed to explain this interaction.